[
    "ural coenzyme in the presence of a cofactor different from the cofactor of the natural enzyme, using either of the screening methods provided by this invention. </p>[0116] Thus, this invention provides an engineered enzyme that functions with a cofactor which is different from cofactors the enzymes naturally uses evolved by this method. </p>[0117] The foregoing embodiments of the subject invention may be accomplished according to the guidance which follows. Certain of the foregoing embodiments are exemplified. Sufficient guidance is provided for a skilled artisan to arrive at all of the embodiments of the subject invention. </p>[0118] Also disclosed is a compound having the formula: </p>H1\u2014Y\u2014H2 </p>[0119] wherein H1 is methorexate or an analog thereof; </p>[0120] wherein H2 is capable of binding to a receptor, and </p>[0121] wherein Y is a moiety providing a covalent linkage between H1 and H2, which may be present or absent, and when absent, H1 is covalently linked to H2.H2 may be Dex or an analog thereof. </p>[0122] When H1 is Mtx, then H2 may be Dex or an analog thereof. </p>[0123] The compound may also have the formula Mtx\u2014Y\u2014H2, and the formula Dex-Y-Mtx. The compound may also have the formula:  \n<img id=\"EMI-C00001\" path=\"US20020004202A1-20020110-C00001.TIF\" file=\"https://surechembl.org/api/assets/attachment/15441397/US/20020110/A1/020020/00/42/02/US20020004202A1-20020110-C00001.TIF\"/>\n</p>[0124] In the compound, wherein H2 may be capable of binding to a receptor with an IC50 of less than 100 mM; or an IC50 of less than 10 mM; or an IC50 of less than 1 mM; or an IC50 of less than 100 uM; or an IC50 of less than 10 uM; or an IC50 of less than 1 pM; or an IC50 of less than 100 nM; or an IC50 of less than 10 nM; or an IC50 of less than 1 nM.  \n<img id=\"EMI-C00002\" path=\"US20020004202A1-20020110-C00002.TIF\" file=\"https://surechembl.org/api/assets/attachment/15441395/US/20020110/A1/020020/00/42/02/US20020004202A1-20020110-C00002.TIF\"/>\n</p>[0125] Also disclosed is a complex between the compound having the formula H1\u2014Y\u2014H2 and a fusion protein which comprises a binding domain capable of binding to methotrexate, wherein H1 of the compound binds to the binding domain of the fusion protein. The binding domain may be that of the DHFR receptor. </p>[0126] In complex, H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 100 nM; or an IC50 of less than 10 nM; or an IC50 of less than 1 nM; or an IC50 of less than 100 pM; or an IC50 of less than 10 pM; or an IC50 of less than 1 pM. </p>[0127] In the complex, the fusion protein may be DHFR-LexA, or DHFR-B42. </p>[0128] Also disclosed is a cell comprising the complex. </p>[0129] Also disclosed is a method of dimerizing two fusion proteins inside a cell using the compound having the formula H1\u2014Y\u2014H2, comprising the steps of a) providing a cell that expresses a first fusion protein which comprises a binding domain that binds to Hl and second fusion protein which comprises a binding domain that binds to H2, and b) contacting the compound having the formula H1\u2014Y\u2014H2 with the cell so as to dimerize the two fusion proteins. </p>[0130] In the method, the first fusion protein or the second fusion protein may be DHFR-(DNA-binding domain); or the first fusion protein or the second fusion protein may be DHFR-(transcription activation domain). </p>[0131] Also in the method, the first fusion protein or the second fusion protein may be DHFR-LexA; or first fusion protein or the second fusion protein is DHFR-B42. </p>[0132] Also disclosed is a method for identifying a molecule that binds a known target in a cell from a pool of candidate molecules, comprising: </p>[0133] (a) covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety or an analog of methotrexate to form a screening molecule; </p>[0134] (b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion p"
]